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Abstract
Transthoracic Doppler echocardiographic-derived coronary flow reserve is an useful
hemodynamic index to assess dysfunction of coronary microcirculation. Isolated coronary
microvascular abnormalities are overt by reduced coronary flow reserve despite normal epicardial
coronary arteries. These abnormalities may occur in several diseases (arterial hypertension,
diabetes mellitus, hypercholesterolemia, syndrome X, aortic valve disease, hypertrophic
cardiomyopathy and idiopathic dilated cardiomyopathy). The prognostic role of impaired
microvascular coronary flow reserve has been shown unfavourable especially in hypertrophic or
idiopathic dilated cardiomyopathies. Coronary flow reserve reduction may be reversible, for
instance after regression of left ventricular hypertrophy subsequent to valve replacement in
patients with aortic stenosis, after anti-hypertensive treatment or using cholesterol lowering drugs.
Coronary flow reserve may increase by 30% or more after pharmacological therapy and achieve
normal level >3.0. In contrast to other non invasive tools as positron emission tomography, very
expensive and associated with radiation exposure, transthoracic Doppler-derived coronary flow
reserve is equally non invasive but cheaper, very accessible and prone to a reliable exploration of
coronary microvascular territories, otherwise not detectable by invasive coronary angiography,
able to visualize only large epicardial arteries.
The concept of coronary flow reserve (CFR) and 
transmural reduction of CFR
The coronary arterial tree consists of four basic segments.
Epicardial coronary arteries give off small transmural pen-
etrating arteries, which have branches in the myocardial
layers. These branches are defined arterioles, terminating
in capillary vessels, directly supplying myocardial cells.
Each of these coronary segments produces different level
and degree of resistance to coronary blood flow. Normal
(non-stenosed) large epicardial coronary arteries play a
minor role in the regulation of coronary vascular resist-
ance and act mainly as conductance (conduit) vessels.
Most of the resistance, which opposes coronary blood
flow, arises from resistance arterioles. The resistance is
manifest by decreased coronary perfusion pressure. The
percent distribution of the length and resistance of indi-
vidual segments of the coronary vascular tree is summa-
rised in Table 1 and depicted in Figure 1.
The difference between coronary blood flow correspond-
ing to flow autoregulation plateau at rest and coronary
blood flow after maximal vasodilatation is traditionally
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defined as coronary flow reserve (CFR) [1-6]. CFR is usu-
ally calculated as the ratio of maximal (hyperemic) to rest-
ing coronary blood flow (Figure 2). CFR is an important
functional parameter to understand the pathophysiology
of coronary circulation and can be used to examine the
integrity of microvascular circulation.
The assessment of regional coronary flow reveals marked
spatial heterogeneity of CFR across the myocardial wall.
According to the model of Hoffman [2], the highest CFR
is that measurable in the subepicardial layer of myocar-
dium. In relation to a transmural flow reduction, CFR is
significantly lower in the subendocardial layer, also due to
elevated left ventricular (LV) diastolic pressure increasing
extravascular compressive forces. As a result of this trans-
mural coronary flow distribution, CFR is exhausted firstly
in the subendocardial layer [2] (Figure 2). The lower limit
of coronary flow autoregulation is unfavourably shifted to
the higher value of coronary perfusion pressure in the sub-
endocardial layer as compared with the subepicardial
layer (i.e. 55–65 mm Hg versus 30–40 mmHg, respec-
tively) [5] (Figure 2). According to Hoffman [2] the reduc-
tion of global CFR from 4.0 to 2.0 could be associated
with the loss of flow reserve in a part or all of the suben-
docardial layer of the myocardium.
In human studies, due to limited spatial resolution of pos-
itron emission tomography (PET), the demonstration of
subendocardial hypoperfusion has been made possible
only in the hypertrophied myocardium [7]. In patients
with aortic valve stenosis and normal epicardial coronary
arteries [7], subendocardial CFR (1.43 ± 0.33) was lower
than subepicardial CFR (1.78 ± 0.35; P = 0.01). In the sub-
group of severe aortic stenosis (aortic valve area <0.8 cm2)
CFR was <2.0 both at subendocardial and subepicardial
levels and in two of these patients subendocardial CFR
was <1.0 (lack of CFR).
An alternative approach to document transmural steal
phenomenon is the calculation of subendocardial/sub-
Table 1: Distribution of coronary resistance in normal coronary arterial bed.
Large epicardial 
arteries
Medium-sized and 
small arteries
Arterioles Capillaries
Diameter >1000 µm 1000–100 µm. 100–10 µm< 1 0   µm
% of total resistance 5% 15–25% 400–100 µm 50–60% 20%
% length of coronary bed 5–10% 15–25% 60–75%
Sequential decrease of coronary perfusion pressure in consecutive segments of coronary vasculature Figure 1
Sequential decrease of coronary perfusion pressure in consecutive segments of coronary vasculature. The largest fall in per-
fusion pressure occurs in coronary resistance arterioles.
Large epicardial arteries Medium-
sized and
small arteries
15 35 80 95 P = 100
mmHg
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epicardial flow ratio [8,9]. A hyperemic value of subendo-
cardial / subepicardial flow ratio <0.8 (i.e.,
subendocardial flow is at least 20% lower than subepicar-
dial) has been proposed as marker of subendocardial
hypoperfusion. In some patients with hypertrophic
cardiomyopathy (HCM), subendocardial flow was 40%
lower than subepicardial flow (ratio = 0.6) after infusion
of a vasodilator agent [8,9].
Magnetic resonance imaging (MRI) with gadolinium con-
trast agent, has higher resolution and appears more sensi-
tive providing the opportunity to assess even patients
without left ventricular hypertrophy, i.e. with normal wall
thickness [10]. Accordingly, cardiac MRI demonstrates
subendocardial hypoperfusion in patients with syndrome
X during the intravenous administration of adenosine
when compared with healthy control subjects who
showed increase of subendocardial perfusion after
induced hyperemia [10].
The lower limit of normal CFR and criteria for 
normal reference values
An important practical issue is to confirm in clinical stud-
ies that the lower limit of normal CFR is >3.0. This aspect
is summarised in Table 2.
Before defining the normal value of CFR, we should iden-
tify appropriately reference groups of healthy subjects. In
order to achieve this aim, non invasive studies present a
particularly useful approach because we may recruit any
subject who gives informed consent to examination. The
perfect candidate is a healthy volunteer without
Transmural distribution of coronary flow reserve (CFR); CFR subepicardial > CFR subendocardial Figure 2
Transmural distribution of coronary flow reserve (CFR); CFR subepicardial > CFR subendocardial.
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cardiovascular signs/symptoms and/or risk factors for
both vascular dysfunction and coronary artery disease. In
contrast, invasive studies are performed in subjects who
complain about chest pain or other cardiac symptoms,
implying that coronary microvascular vasodilator dys-
function may limit coronary blood flow and determines
angina despite normal coronary epicardial arteries. Two
studies [18,19] have shown that such a coincidence is
quite frequent. Bearing in mind this limitation it has been
proposed by Baumgart et al [20] that in invasive measure-
ments normal limits of CFR may be derived only from
highly selected subjects according to the following
restricted criteria:
- truly normal epicardial arteries confirmed by intracoro-
nary ultrasound examination
- age <50 years
- absence of symptoms (in addition, we propose an oblig-
atory absence of risk factors for vascular/endothelial
dysfunction).
These highly-selected subjects (table 2) exhibit CFR mark-
edly exceeding the cut-off point of 3.0, this value is near to
the highest value obtained in an athletes' populations
(CFR > 5.0).
Table 2: Comparison of CFR using different methods in reference control groups.
Number of patients Method CFR Reference
17 (HTX) DI 5.0 ± 0.3* [11]
26 (HTX) DI 5.2 ± 1.3* [12]
18 (young subjects) PET 4.1 ± 0.9 [13]
22 (elderly subjects) PET 3.0 ± 0.7 [13]
10 D.TTE 4.5 ± 0.9 [14]
10 PET 4.1 ± 1.0 [15]
10 D.TTE 5.2 ± 1.6 [16]
19 D.TTE 3.7 ± 0.7 [17]
26 (athletes) D.TTE 5.9 ± 1.0 [17]
* intracoronary papaverine
CFR = coronary flow reserve; DI. = invasive intracoronary Doppler, D.TTE = noninvasive transthoracic Doppler echocardiography, HTX = routine 
assessment of coronary flow reserve early after heart transplantation
Table 3: Three groups of factors limiting CFR:
1. Increase of resting coronary blood flow due to increased myocardial oxygen demand as a result of:
• tachycardia
• increased myocardial contractility
• myocardial hypertrophy
2. Decrease of maximal (hyperemic) coronary blood flow:
• epicardial coronary artery stenosis
• decrease mean aortic pressure = coronary perfusion pressure e.g. aortic insufficiency, exaggerate response to vasodilator agent
• wall thickening (remodeling) of resistance arterioles
• reduced density of arterioles
• cardiomyocyte hypertrophy
• perivascular fibrosis
• interstitial fibrosis
• endothelial dysfunction
• increased blood viscosity: policythemia, macroglobulinemia
• elevated LV diastolic pressure increasing extravascular compressive forces and resistance (particularly in subendocardial layer).
3. Shift to the right in the pressure-flow relation through maximally dilated vessels due to an increase in zero flow pressure line:
• increased left ventricular diastolic pressure
• tachycardia
• myocardial hypertrophyCardiovascular Ultrasound 2005, 3:18 http://www.cardiovascularultrasound.com/content/3/1/18
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The recruitment of reference controls subjects with nor-
mal epicardial coronary arteries verified by intracoronary
ultrasound is crucial as indicated by the following exam-
ple. Positive exercise myocardial scintigraphy, primarily
considered as false positive in relation to angiographically
normal coronary vessels, may frequently turn out to be
true positive when control intracoronary ultrasound
reveals vascular lesions [21]. In this clinical setting, CFR is
a fairly good predictor of "soft lesions", non-visualizable
even by coronary angiography [21].
Baumgart [20] proposed a range of age <50 years since
PET revealed a significantly higher CFR in younger than in
the elderly subjects (Table 2). Other investigators [13]
demonstrated that aging-induced reduction of CFR is a
result of increased coronary blood flow at rest, whereas
maximal blood flow remained relatively unchanged
during the years. Only over 70 years, maximal coronary
blood flow is reduced. According to these findings [20],
the lower limit of normal CFR should be reasonably fixed
to 3.0 for subjects up to the age of 50.
Factors limiting coronary flow reserve
In general, the reduction of CFR may be associated with
three main kinds of abnormalities [2,3,22,23] (Table 3,
Figure 3) and it is even possible for two factors to co-oper-
ate simultaneously. However, it has to be taken into
account that epicardial coronary artery stenosis, the most
visible factor of patients with angina pectoris (examined
alone by coronary angiography in daily practice), is only
one possible determinant in contrast to several other
multi-factorial mechanisms involving coronary microvas-
cular dysfunction. Structural changes (remodelling) in
coronary microcirculation can themselves be responsible
of CFR reduction. By using myocardial biopsy, some stud-
ies have provided the opportunity to compare pathomor-
Complexity of CFR concept Figure 3
Complexity of CFR concept. Percent values on the curves 
represent the severity of coronary epicardial stenosis.
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Table 4: CFR in microvascular disease with normal coronary 
angiogram.
Clinical setting CFR
HCM pediatric pts (septum) [29] 0.84 ± 0.33
Control 2.94 ± 0.35
Aortic insufficiency [30] 1,67 ± 0,4
Control 4,03 ± 0,52
Dilated cardiomyopathy [31] 2.2 ± 0.8
Control 3.3 ± 0.8
Dilated cardiomyopathy [32] 2,0 ± 0,6
NYHA class I 2,43 ± 0,4
NYHA class II 2,21 ± 0,2
NYHA class III 1,98 ± 0,3
NYHA class IV 1,78 ± 0,3
Control 3,2 ± 0,5
Diabetes [33]
Without retinopathy 2.8 ± 0.3
with early diabetic retinopathy 2.3 ± 0.3
with slightly advanced retinopathy 1.6 ± 0,2
Control 3.3 ± 0,4
Patients with chest pain and [34] 
Without ST depression in ECG exercise test 3.0 ± 0.6
With up-slope ST depression in ECG exercise test 3.1 ± 0.6
With flat ST depression in ECG exercise test 2.1 ± 0.6
With down-slope ST depression ECG exercise test 2.0 ± 0,4
Hypertension [35] 
Concentric remodeling 2.0 ± 0.7
Concentric hypertrophy 2.3 ± 0.8
Eccentric hypertrophy 2.9 ± 0.6
Normal geometry 2.7 ± 0.4
Control 4.2 ± 0.5
Table 5: Findings of CFR in some diseases associated to coronary 
microvascular dysfunction and in healthy controls [36]
Clinical setting CFR
Hypertrophic cardiomyopathy 2.21 ± 0.2
Dilated cardiomyopathy 1.9 ± 0.2
Syndrome X 2.27 ± 0,3
Control group 3.3 ± 0.3Cardiovascular Ultrasound 2005, 3:18 http://www.cardiovascularultrasound.com/content/3/1/18
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phological changes of coronary microcirculation and CFR
reduction, documenting the relationship between mor-
phological and hemodynamic abnormalities. In patients
with hypertrophic cardiomyopathy, a reduced arteriolar
lumen was associated to a reduced CFR [24,25]. Also in
hypertensive patients [26] reduced CFR correlated with
increased coronary arteriolar wall thickness, i.e, arteriolar
remodelling. A decreased arteriolar wall/lumen ratio cor-
relates with reduction of CFR as well as with abnormali-
ties of derived parameters as coronary resistance reserve.
All together, these studies strongly support the hypothesis
that the microvascular factor is a further important con-
tributor (as extravascular, myocardial factor, i.e. LV hyper-
trophy, excessive intramyocardial pressure) of CFR
reduction. From a pathophysiological point of view,
coronary microvascular disease is associated with alterna-
tive ischemic cascade where stress test induces chest pain,
ECG ST-segment depression and myocardial scintigraphic
perfusion defect despite the lack of changes in echocardi-
ographic-derived regional myocardial wall motion [27].
How much coronary microvascular disease may 
reduce CFR?
In a recent study Voci et al. [28] minimised the role of
reduced microvascular CFR, probably underestimating
the unfavourable influence of impaired coronary micro-
circulation on prognosis. These authors stated that
patients die of epicardial coronary artery disease, not of
microvascular disease. In other studies [29-35], however,
patients with no or minimal coronary stenosis of epicar-
dial coronary arteries exhibited a significantly blunted
CFR in relation to microvascular abnormalities induced
by various cardiovascular diseases (Table 4). Several
patients had markedly reduced CFR < 2.0 and in some
pediatric patients with hypertrophic cardiomyopathy CFR
was <1.0 [29]. On these grounds, the authors [29] postu-
lated that non-hypertrophic free wall steals the blood flow
from the hypertrophied septum after a vasodilator infu-
sion. A gradual decrease of CFR, parallel to more
advanced stages of microvascular disease, was observed in
diabetic patients, patients with syndrome X and also
hypertensive patients without overt coronary artery steno-
sis (Table 4). In this view it is notable the experience of
Rigo [36], who collected CFR values measured by tran-
sthoracic Doppler echocardiography in large population
samples affected by various cardiac diseases (Table 5). It is
also of interest that the reduction of CFR is reversible in
some cases, for instance after regression of LV hypertrophy
subsequent to aortic valve replacement in patients with
aortic valve stenosis, after anti-hypertensive treatment or
even after cholesterol treatment [37-42]. (Table 6). Impor-
tantly, even drugs of the same group (angiotensin convert-
ing enzyme inhibitors [perindopril versus enalapril] and
statins [simvastatin versus pravastatin]) exhibited differ-
ent influence on CFR (Table 6). After simvastatin
treatment [39], the percent increase of CFR correlated
with percent decrease of cholesterol and triglycerides
levels.
Interestingly, in patients with epicardial coronary artery
stenosis and severe hypercholesterolemia, single LDL-
apheresis improved microcirculation by increasing CFR
from 1.91 ± 0,68 to 2.48 ± 0.68 [43]. This finding demon-
strates that, even after single LDL-lowering intervention,
some patients can move quickly from a group where
PTCA appears to be required (corresponding to CFR < 2.0)
to a group with CFR >2.0, where PTCA may not be needed
anymore.
Vasodilators inducing hyperemia
Two main pharmacological vasodilators, adenosine and
dipyridamole, are used in humans to recruit CFR. The
characteristics of these agents are compared in Table 7.
These agents have an advantage over exercise and dob-
utamine, which represent submaximal stimuli for coro-
nary flow reserve and are much more technically
demanding for ultrasound imaging of CFR [44]. Either
adenosine or dipyridamole were used in referred studies
of Tables 4, 5, where only studies with control group are
reported. The control group provides an opportunity to
compare how much CFR is reduced (sometimes more
Table 6: Increase in CFR in microvascular disease after treatment.
Disease CFR Effect of treatment p
Aortic stenosis [37] 1.8 ± 0.5 2.6 ± 0.7 (valve replacement) <0.05
Familial hypercholesterolemia [38] 2.3 ± 0.6 3.3 ± 1.2 (simvastatin) <0.05
Hypercholesterolemia [39] 2.4 ± 0.7 3.2 +1.2 (simvastatin) <0.05
2.2 ± 0.7 2.3 ± 0.6 (pravastatin) >0.05
Arterial hypertension [40] 1.9 ± 0.31 2.1 ± 0.3 (nebivolol) <0.05
Arterial hypertension [41] 2.1 ± 0.6 3.5 ± 1.9 (perindopril) <0.05
Arterial hypertension [42] 2.4 ± 0.7 2.4 ± 0.6 (enalapril) >0.05
2.7 ± 0.8 3.7 ± 1.8 (verapamil) <0.05Cardiovascular Ultrasound 2005, 3:18 http://www.cardiovascularultrasound.com/content/3/1/18
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than 50%) in patients with different involvement of coro-
nary microvascular disease.
Prognostic value of impaired microvascular CFR
The prognostic role of impaired microvascular CFR has
been found unfavourable. In a study by Marks at al. [45],
reduced CFR due to unspecified microvascular disease
predicted increased mortality – 20% vs. 7% in a group
with normal CFR (p < 0.016). The relationship between
unfavourable prognosis and reduced CFR in patients with
hypertrophic or idiopathic dilated cardiomyopathies was
recently reported [46,47]. In other two studies where
patients were divided according to CFR tercentyle [48] or
maximally stimulated coronary blood flow tercentyle
[49], the subgroup defined as the lowest tercentyle had
the worst outcome. The markedly blunted maximal blood
flow was related with poor prognosis not only in HCM
patients [49] but also in patients with idiopathic dilated
cardiomyopathy (DCM) [50]. In this clinical setting,
strongly depressed dipyridamole-stimulated maximal cor-
onary blood flow was associated, with a 3.5 relative risk of
death or development or progression of heart failure.
These results support the hypothesis that chronic myocar-
dial hypoperfusion or repetitive myocardial ischemia
attributable to abnormal coronary microcirculatory flow
could exert a detrimental role in the evolution of idio-
pathic LV dysfunction toward overt DCM. Cecchi et al.
[49] hypothesised that coronary microvascular dysfunc-
tion may represent a common pathway leading to a dis-
ease progression in different cardiomyopathies, including
conditions as aortic valve stenosis and hypertensive heart
disease.
Limitations and hypothesis
In several of the referred reports, dipyridamole was used
to produce vasodilating hyperemia. Adenosine (140 ug/
kg/min) has been shown to be either similar [51] or more
potent vasodilator agent [52] than high-dose dipyrida-
mole (0.84 mg/Kg). In relation to the possibility that
dipyridamole-recruited CFR could be submaximal, we can
not be absolutely sure about the appropriateness of the
lower limit of normal CFR = 3.0. To resolve this problem,
apart from vasodilator selection, the choice of appropriate
control groups is also due, by excluding smokers and
patients with arterial hypertension, hyperlipidemia,
obesity, diabetes mellitus, and, possibly, those affected by
hyperhomocysteinemia. These highly selecting criteria
probably was not fulfilled in previous studies, in
particular the oldest, where the newest recognized factors
limiting CFR were not yet known. Recently, new evidence
has been given that in healthy subjects even single exposi-
tion to passive smoking [53], fat meal inducing hypertrig-
lyceridemia [54], hyperhomocysteinemia [55], and
estrogen decrease in menstrual phase of cycle [56] can
reduce CFR by approximately 30%. Thus, we can not be
certain that normal CFR starts from 3.0 because CFR val-
ues higher than 5.0 were recorded in humans. Interest-
ingly, in a transplanted heart which can not be equivalent
of intact heart in healthy volunteers, CFR may also
achieved more 5.0 (see Table 2). This high value is proba-
bly the result of intracoronary papaverine, which is not
used currently. However, these findings strongly supports
the hypothesis that CFR may achieve much higher level
than 3.0.
As regard validation of a non-invasive methods, transtho-
racic Doppler echocardiography closely agrees with intra-
coronary Doppler flow wire results in assessing CFR.
Good correlation of non-invasive and invasive Doppler
assessment of CFR has been shown both in LAD [57] and
RCA [58]. The feasibility of transthoracic Doppler
echocardiography to detect coronary flow is 80–98% in
LAD, 50–87% in RCA and 43–72% in Cx [6,36,59].
Conclusion
Isolated coronary microvascular abnormalities are overt
by reduced CFR despite normal epicardial coronary
arteries. These abnormalities may occur in several diseases
(arterial hypertension, diabetes mellitus, hypercholestero-
lemia, syndrome X, aortic valve disease, hypertrophic car-
diomyopathy and idiopathic dilated cardiomyopathy).
The prognostic role of impaired microvascular CFR has
been shown unfavourable, in particular in patients with
hypertrophic or idiopathic dilated cardiomyopathies. CFR
Table 7: Comparison between adenosine and dipyridamle characteristics
Adenosine Dipyridamole
Duration of action 30 sec 30 min
Time to max. Effect 30–55 sec 6–16 min
Advantage Short action, short-lasting adverse effects prolonged action allow to assess CFR and wall motion 
abnormalities during the same examination
Disadvantage Frequent- hyperventilation
Rare – bradycardia, AV block, hypotension, flushing, 
headache,
possibility of antidote-resistance prolonged ischemia, 
hypotension, flushing, headache, hyperventilation,Cardiovascular Ultrasound 2005, 3:18 http://www.cardiovascularultrasound.com/content/3/1/18
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reduction may be reversible, for instance after regression
of left ventricular hypertrophy subsequent to valve
replacement in patients with aortic stenosis, after anti-
hypertensive treatment or using cholesterol lowering
drugs. CFR may increase by 30% or more after pharmaco-
logical therapy and achieve level >3.0. In contrast to other
non invasive tools as PET, very expensive and associated
with radiation exposure, transthoracic Doppler-derived
CFR is equally non invasive but cheaper, very accessible
[60] and prone to a reliable exploration of coronary
microvascular territories, not detectable by invasive coro-
nary angiography, able to visualize only large epicardial
arteries.
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